Skip to Content Skip to Search

Our approach

Harnessing the “multiplier effect”: Science x Technology x Culture

In Pharmaceuticals, we focus on science related to the immune system, the use of human genetics and advanced technologies. Driving our R&D is the “multiplier effect” – Science x Technology x Culture – which was introduced in 2018 by Chief Scientific Officer and President, R&D Dr Hal Barron.

This approach will help us discover, develop and deliver transformational medicines faster. It means we will prioritise molecules that have a greater chance of becoming a medicine that will improve patients’ lives.

In our Vaccines business, we balance two priorities: a pipeline of innovative candidate vaccines, and lifecycle management of our existing vaccines. Our goal is to protect more people in more geographies.

As technology and our understanding of science and the human body move forward, we will be able to explore new breakthroughs and apply them to some of the world’s biggest health challenges. We have continually pushed the boundaries in vaccine science. Our advances include the development of recombinant DNA-based vaccines as well as the introduction of a variety of adjuvant systems.

Here are the three elements of the “multiplier effect”:


Discovery and development are risky. Fewer than 10% of drugs in clinical testing become medicines.


Our R&D approach involves significant investment in advanced technologies.

We are building artificial intelligence and machine learning capability to help us better understand and interpret genetics and genomic data. Our investments in functional genomics include CRISPR technology, which is helping us to discover and validate potential targets. And we continue to develop our strengths in cell and gene therapy.

Can the human body become a factory for its own vaccines?

Dr Emmanuel Hanon, Senior Vice President and Head of Vaccines R&D, discusses how a new revolution in life science is changing the way we create vaccines.


Our unique culture brings our R&D to life.